GSK wins FDA approval of Blenrep for multiple myeloma
Source: SeekingAlpha
2025-10-23 17:27:02 ET
More on GSK
- GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon
- GSK's Hidden Growth Engines Beyond HIV And Oncology
- GSK: Walmsley Out, Miels In - I'm Watching The CEO Transition From The Sidelines
- Alector slumps on late-stage trial setback for GSK-partnered dementia candidate
- Astra, GSK up after report on U.K. – U.S. drug pricing deal
Read the full article on Seeking Alpha
For further details see:
GSK wins FDA approval of Blenrep for multiple myeloma
Johnson & Johnson
NASDAQ: JNJ
JNJ Trading
-0.1% G/L:
$243.60 Last:
2,836,439 Volume:
$244.21 Open:
JNJ Latest News
March 13, 2026 12:35:00 pm
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
March 12, 2026 08:00:00 am
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
March 09, 2026 09:54:00 am
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment
JNJ Stock Data
$577,845,337,264
2,385,202,151
0.01%
2802
N/A
Pharmaceuticals
Healthcare
US
New Brunswick
